

Electronic Acknowledgement Receipt

EFS ID:	3995655
Application Number:	10566878
International Application Number:	
Confirmation Number:	9964
Title of Invention:	Use of recombinant or synthetic gelatin-like proteins as stabiliser in lyophilized pharmaceutical compositions
First Named Inventor/Applicant Name:	Andries Van Es
Customer Number:	00545
Filer:	Roger Pitt/Beata White
Filer Authorized By:	Roger Pitt
Attorney Docket Number:	0807620.00111
Receipt Date:	24-SEP-2008
Filing Date:	02-FEB-2006
Time Stamp:	12:58:41
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 1860
RAM confirmation Number	7880
Deposit Account	080570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	VAN_ES_10566878_Cover_Letter.pdf	27347 e007c5f1a94224908f94b1187bc294a0f6b6	no	1
Warnings:					
Information:					
2		VAN_ES_10566878_Amendment_after_Final.pdf	45743 6c7db9a0cb27190752e036e09cc0b292084637	yes	20
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment After Final		1	1	
	Claims		2	9	
	Amendment After Final		10	20	
Warnings:					
Information:					
3	Request for Continued Examination (RCE)	VAN_ES_USAN_10566878_RCE.pdf	181607 5612111cae8dbd9ed9ac1e17700a9fba647b	no	1
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
4	Extension of Time	VAN_ES_10566878_Petition_for_Extension.pdf	155721 8298a07070bec42924d274e181f5c381428542	no	1
Warnings:					
Information:					
5	Fee Worksheet (PTO-06)	fee-info.pdf	32086 176157dabdd961794c0f47e08aa5330a996c7f5	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			442504		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.